




>>Entry Name: Ritanserin, BAN, INN, USAN

Synonym(s): 6-[2-[4-[Bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, 9Cl. 6-[2-[4-(4,4'-Difluorobenzhydrylidene)piperidino]ethyl]-7-methyl[1,3]thiazolo[3,2-a]pyrimidin-5-one. R 55667



CAS Registry Number: 87051-43-2

Molecular Formula: C<sub>27</sub>H<sub>25</sub>F<sub>2</sub>N<sub>3</sub>OS

Molecular Weight: 477.577

Accurate Mass: 477.168638

Percentage Composition: C 67.90%; H 5.28%; F 7.96%; N 8.80%; O 3.35%; S 6.71%

Use/Importance: 5-HT<sub>2</sub>-receptor and dopamine D<sub>2</sub>-receptor antagonist. Shows antiparkinsonian activity, anxiolytic. Antihypertensive agent

Physical Description: Cryst. (MeCN)

Melting Point: Mp 145.5°

Calculated Log P Data: Log P 4.87 (uncertain value) (calc)

#### References:

- Eur. Pat.*, 1984, *Janssen*, 110 435; *CA*, **102**, 6522t, (*synth, pharmacol*)  
Goodwin, G.M. *et al.*, *Br. J. Pharmacol.*, 1985, **84**, 743, (*pharmacol*)  
Vinick, F.J. *et al.*, *Annu. Rep. Med. Chem.*, 1986, **21**, 1, (*rev*)  
Kennis, L.E.J. *et al.*, *Drug Dev. Res.*, 1986, **8**, 133; 187, (*rev, pharmacol*)  
Sandrini, G. *et al.*, *Eur. J. Pharmacol.*, 1986, **130**, 311, (*pharmacol*)  
Larsson, M. *et al.*, *Methods Find. Exp. Clin. Pharmacol.*, 1987, **9**, 349, (*hplc, anal*)  
Timmerman, P. *et al.*, *Biomed. Environ. Mass Spectrom.*, 1989, **18**, 498, (*gc, ms*)  
Henderson, J. *et al.*, *Clin. Exp. Neurol.*, 1992, **29**, 277, (*pharmacol, human*)  
*Martindale, The Extra Pharmacopoeia*, 30th edn., *Pharmaceutical Press*, 1993, 615